A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy
Author:
Affiliation:
1. Pharmerit ‐ an OPEN Health Company Bethesda
2. Pfizer, Inc New York New York
3. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas
Funder
Pfizer
University of Texas MD Anderson Cancer Center
National Institutes of Health
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33072
Reference27 articles.
1. Daurismo (Glasdegib) [package insert]. Pfizer Inc;2018.
2. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
3. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
4. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.
5. Q-TWiST: What really matters to the cancer patient?
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review;Future Oncology;2023-04
2. lncRNA-miRNA-mRNA Interaction Networks Regulation in Hematological Malignancies;Reference Module in Biomedical Sciences;2023
3. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML;Journal of Hematology & Oncology;2021-07-13
4. Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases;Clinical Lymphoma Myeloma and Leukemia;2021-04
5. Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms;Expert Review of Hematology;2020-12-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3